Navigation Links
Lilly Withdraws Application for Additional U.S. Indication for Cymbalta(R) for Chronic Pain
Date:11/28/2008

ieved to potentiate the activity of these chemicals in the central nervous system (brain and spinal cord). While the exact mechanism of action of Duloxetine is unknown, scientists believe its effects on depression and anxiety symptoms, as well as its effect on pain perception, may be due to increasing the activity of serotonin and norepinephrine in the central nervous system.

Duloxetine is approved in the United States for the acute and maintenance treatment of major depressive disorder, the acute treatment of generalized anxiety disorder, and the management of diabetic peripheral neuropathic pain and fibromyalgia in adults age 18 years and older. Duloxetine is not approved for use in pediatric patients.

Important Safety Information

Duloxetine is approved to treat major depressive disorder and generalized anxiety disorder, and to manage diabetic peripheral neuropathic pain and fibromyalgia. Antidepressants can increase suicidal thoughts and behaviors in children, adolescents, and young adults. Patients should call their doctor right away if they experience new or worsening depression symptoms, unusual changes in behavior, or thoughts of suicide. Be especially observant within the first few months of treatment or after a change in dose. Duloxetine is approved only for adults 18 and over.

Duloxetine is not for everyone. Patients should not take Duloxetine if they have recently taken a type of antidepressant called a monoamine oxidase inhibitor (MAOI), are taking Mellaril(R) (thioridazine), or have uncontrolled glaucoma. Patients should speak with their doctor about any medical conditions they may have including kidney problems, glaucoma, or diabetes. Patients should talk to their doctor if they have itching, right upper belly pain, dark urine, yellow skin or eyes, or unexplained flu-like symptoms, which may be signs of liver problems. Severe liver problems, sometimes fatal, have been repor
'/>"/>

SOURCE Eli Lilly and Company
Copyright©2008 PR Newswire.
All rights reserved

Page: 1 2 3 4

Related medicine technology :

1. Daiichi Sankyo and Lilly Respond to Speculation on Status of Prasugrel New Drug Application
2. Lilly and Deciphera Pharmaceuticals Announce Licensing and Collaboration Agreement
3. Lilly Announces Initiation of Second Global Phase III Trial of Investigational Alzheimers Disease Compound
4. Insulin Analogues From Novo Nordisk, Eli Lilly and Sanofi-Aventis Will Drive Growth in the Type 1 Diabetes Drug Market
5. Phase II Data on Lillys Antibody Show It Affects Amyloid Beta, a Protein Believed To Be Associated with Alzheimers Disease
6. FDA Extends Review Period for Daiichi Sankyo, Lilly Investigative Antiplatelet Drug, Prasugrel
7. Lilly and TransPharma Medical Announce Licensing and Development Agreement
8. Lilly Submits Cymbalta(R) Supplemental New Drug Application for Chronic Pain to U.S. Food and Drug Administration
9. Daiichi Sankyo/Eli Lillys Effient and Astrazenecas Ticagrelor May Offer Advantages in the Treatment of Post-Myocardial Infarction
10. Lilly Launches Its First Phase III Trial for Treatment of Alzheimers Disease
11. Lilly and Transition Therapeutics Announce Licensing and Collaboration Agreement
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:10/1/2014)... -- NeuroCall, Inc., ("NeuroCall") announced today that it recently ... services. Dr. Ricardo Garcia-Rivera , Founder and Chief ... that our quality of service has been recognized by ... support and continuity of care to patients of our ... United States ." NeuroCall currently ...
(Date:10/1/2014)... LOUIS , Oct. 1, 2014  Express Scripts ... two nationally available 2015 Express Scripts Medicare ® ... pharmacy network featuring Walgreens (NYSE: WAG ) ... more value, choice and clinical support  for their Medicare ... Express Scripts Medicare Value or Choice ...
(Date:10/1/2014)... 2014 Ardelyx, Inc. (NASDAQ: ... focused on cardio-renal, gastrointestinal and metabolic diseases, ... patient Phase 2b clinical trial evaluating tenapanor ... (IBS-C).  Results from this study demonstrated statistically ... symptoms for tenapanor-treated patients compared to patients ...
Breaking Medicine Technology:NeuroCall Awarded Joint Commission Accreditation 2Express Scripts Collaborates with Walgreens to Create Value-Driven Medicare Prescription Drug Plan Pharmacy Network 2Express Scripts Collaborates with Walgreens to Create Value-Driven Medicare Prescription Drug Plan Pharmacy Network 3Express Scripts Collaborates with Walgreens to Create Value-Driven Medicare Prescription Drug Plan Pharmacy Network 4Ardelyx Reports Positive Results from Its Phase 2b Clinical Trial Evaluating Tenapanor in IBS-C Patients 2Ardelyx Reports Positive Results from Its Phase 2b Clinical Trial Evaluating Tenapanor in IBS-C Patients 3Ardelyx Reports Positive Results from Its Phase 2b Clinical Trial Evaluating Tenapanor in IBS-C Patients 4Ardelyx Reports Positive Results from Its Phase 2b Clinical Trial Evaluating Tenapanor in IBS-C Patients 5Ardelyx Reports Positive Results from Its Phase 2b Clinical Trial Evaluating Tenapanor in IBS-C Patients 6
... ... Symposium, SAN ... and Systems Medicine, LLC (SM), a,wholly-owned subsidiary of CTI, announced new ... AACR-NCI-EORTC Symposium. "These studies show potential progress toward identifying specific,tumor ...
... and Effective Symptom Control, BOSTON, Oct. ... TSX: SHQ), the global specialty biopharmaceutical company, ... DAYTRANA(TM) (methylphenidate,transdermal system), the Attention Deficit Hyperactivity ... ADHD tolerability,and symptom control improvement in children ...
Cached Medicine Technology:Preclinical Studies Show Potential Progress Toward Identifying Specific Tumor Types With Higher Likelihood of Demonstrating Response to Anti-Cancer Compounds Early in Clinical Development 2Preclinical Studies Show Potential Progress Toward Identifying Specific Tumor Types With Higher Likelihood of Demonstrating Response to Anti-Cancer Compounds Early in Clinical Development 3Preclinical Studies Show Potential Progress Toward Identifying Specific Tumor Types With Higher Likelihood of Demonstrating Response to Anti-Cancer Compounds Early in Clinical Development 4Preclinical Studies Show Potential Progress Toward Identifying Specific Tumor Types With Higher Likelihood of Demonstrating Response to Anti-Cancer Compounds Early in Clinical Development 5Long-Term 12-Month Safety Data Presented on ADHD Patch DAYTRANA(TM) (methylphenidate transdermal system) 2Long-Term 12-Month Safety Data Presented on ADHD Patch DAYTRANA(TM) (methylphenidate transdermal system) 3Long-Term 12-Month Safety Data Presented on ADHD Patch DAYTRANA(TM) (methylphenidate transdermal system) 4Long-Term 12-Month Safety Data Presented on ADHD Patch DAYTRANA(TM) (methylphenidate transdermal system) 5
(Date:10/1/2014)... Innovations announces the upcoming airing of Innovations with ... 20, 2014 at 7:30 a.m. EST/PT via Discovery Channel. ... scenes to learn about Break the Cycle’s comprehensive dating ... help and information Break the Cycle provides to teens ... abuse, how to navigate the legal system, and provides ...
(Date:10/1/2014)... 01, 2014 NoteSwift Inc., announced today ... 10.0, 12.1 and 13.0. NoteSwift is the bridge between ... to navigate and document clinical information at the point ... creating a patient note by more than half – ... major pain points providers state impedes EHR use according ...
(Date:10/1/2014)... Scientists at the University of Western Australia say ... proteins has the power to knock out mesothelioma in ... new study on their website. Click here to ... UWA School of Pathology and Laboratory Medicine administered anti-CD25, ... with promising results. , “A timed triple immunotherapy ...
(Date:10/1/2014)... in Bahir Dar, Ethiopia, at the occasion of ... gathered some 150 African and international leishmaniasis experts, ... safety and efficacy monitoring plan, carried out ... Sudan, Uganda, and Ethiopia, were presented to key ... to treatment of kala-azar with the combination of ...
(Date:10/1/2014)... October is national Breast Cancer Awareness ... plans while raising money for breast cancer research. Pelican ... Month in the effort to find a cure. ... importance of having access to clean, healthy water. Research ... to certain forms of cancer. , The Problem ...
Breaking Medicine News(10 mins):Health News:Innovations to Explore Breakthroughs in Health and Wellness in Upcoming Episode Airing Monday, October 20, 2014 via Discovery Channel 2Health News:NoteSwift Joins Allscripts Developer Program 2Health News:NoteSwift Joins Allscripts Developer Program 3Health News:New Mesothelioma Study Says Mice Cured by Immuntherapy “Cocktail”, Reports Surviving Mesothelioma 2Health News:Results of large-scale roll out of combination treatment for kala-azar in Eastern Africa 2Health News:Pelican Water Supports Breast Cancer Awareness Month with Order Donations 2
... at the Congressional Gold Medal ceremony in the Capitol ... Below are the,Speaker,s remarks:, "Good morning. It is ... the House and Senate to honor Dr. Michael DeBakey. ... Representative Al,Green, and others who worked with them for ...
... CHAPEL HILL, N.C., April 23 Global leaders ... as a powerful tool for competing in today,s ... firm Best Practices, LLC.,The study further reveals -- ... strategic process of transforming raw competitive data,into actionable ...
... Foundation (EGPAF), a world leader in the fight against ... totaling $1 million to researchers to support the development ... MD, PhD, professor of medicine at the University of ... Luzuriaga, MD, professor of pediatrics and director of the ...
... FDAnews and Industry Directions Launch New Study, ... FDAnews and Industry Directions Inc., in close,association with ... manufacturers to respond to a new survey on ... company objectives,business processes and practices, information systems and ...
... protein prevents inflammation, hints of new treatments for disease ... they may have discovered how tumors develop in the ... for gastric cancer. , In a study done on ... Ludwig Institute for Cancer Research (LICR) found that blocking ...
... (NYSE: RAI ) will webcast its conference call ... April 30,2008. The call will begin at 9:30 a.m. ... Reynolds American management team will,discuss RAI,s first-quarter results., ... a listen-only basis,at http://www.ReynoldsAmerican.com . Registration for the ...
Cached Medicine News:Health News:Pelosi: 'By Literally Fixing Broken Hearts, Dr. DeBakey Has Given Hope and Health to Millions' 2Health News:Complimentary Excerpt Available from Best Practices: Pharmaceutical Competitive Intelligence Excellence - Optimizing Data Collection within Approved Guidelines 2Health News:UMass Medical School researchers awarded pediatric HIV vaccine development grant 2Health News:UMass Medical School researchers awarded pediatric HIV vaccine development grant 3Health News:Risk Management: Best Practices for Medical Device Profitability 2Health News:Scientists Discover How Stomach Tumors Form 2Health News:RAI to Webcast First Quarter 2008 Earnings Conference Call 2
... ARUP Laboratories is a national reference ... laboratory research and development. ARUP offers an ... unique medical tests in clinical and anatomic ... ARUP Laboratories' clients include more than half ...
... a national reference laboratory and a worldwide ... ARUP offers an extensive test menu of ... clinical and anatomic pathology. Owned by the ... more than half of the nation's university ...
... Laboratories is a national reference laboratory and ... and development. ARUP offers an extensive test ... tests in clinical and anatomic pathology. Owned ... clients include more than half of the ...
... national reference laboratory and a worldwide leader ... offers an extensive test menu of highly ... and anatomic pathology. Owned by the University ... than half of the nation's university teaching ...
Medicine Products: